

Status: Currently Official on 15-Feb-2025  
Official Date: Official Prior to 2013  
Document Type: USP Monographs  
DocId: GUID-6525900E-52A4-4ED1-8D89-574288EA4C21\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M44830\\_01\\_01](https://doi.org/10.31003/USPNF_M44830_01_01)  
DOI Ref: xd1wp

© 2025 USPC  
Do not distribute

## Levonorgestrel and Ethynodiol Tablets

### DEFINITION

Levonorgestrel and Ethynodiol Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of levonorgestrel ( $C_{21}H_{28}O_2$ ) and NLT 90.0% and NMT 110.0% of the labeled amount of ethynodiol ( $C_{20}H_{24}O_2$ ).

### IDENTIFICATION

- **A.** The retention times of the two major peaks of the *Sample solution* correspond to those of levonorgestrel and ethynodiol in the *Standard solution*, as obtained in the Assay.
- **B.** Finely powder 20 Tablets and transfer a portion of the powder, equivalent to 4 mg of levonorgestrel, to a suitable container. Add 250 mL of a solvent mixture consisting of isooctane and chloroform (3:1). Sonicate the mixture for 3 min, and then stir it by mechanical means for 30 min. Filter the mixture and evaporate the filtrate to dryness in a rotating vacuum evaporator. Dissolve the residue in 3 mL of chloroform, and transfer with a pipet to a 60-mL separator containing 18 mL of isooctane. Rinse the evaporator flask with an additional 3-mL portion of chloroform, and add the rinsing to the separator. Add 10 mL of 1 N sodium hydroxide, shake vigorously, and allow the layers to separate. Discard the lower aqueous phase, and filter the organic phase through 3 g of anhydrous sodium sulfate on filter paper into a 50-mL beaker. Rinse the filter with several small portions of the mixture of isooctane and chloroform (3:1), adding the filtered rinsings to the filtrate, and evaporate under nitrogen on a steam bath to dryness. Dissolve the residue in 1–2 mL of hot toluene, and transfer with a pipet to a small glass vial. Reduce the volume of the solution to 0.1 mL under nitrogen with warming. [NOTE—During this step, any crystals that deposit on the vial wall should be transferred to the bottom, and allowed to redissolve.]

Store the vial containing the clear toluene solution at 4° overnight to allow crystallization to occur. Remove and discard the mother liquor with a pipet, rinse the crystals with two 0.5-mL portions of anhydrous ether, and discard the rinsings. Dry the vial containing the rinsed crystals in a vacuum desiccator at 60° for 4 h.

**Acceptance criteria:** The melting point of the dried crystals of levonorgestrel so obtained is not lower than 220°, using the procedure described under [Melting Range or Temperature \(741\), Class I](#).

### ASSAY

#### • PROCEDURE

**Mobile phase:** Acetonitrile, methanol, and water (35:15:45)

**Standard solution:** 15 µg/mL of [USP Levonorgestrel RS](#) and 3 µg/mL of [USP Ethynodiol RS](#) in *Mobile phase*

**Sample solution:** Transfer a number of Tablets, equivalent to 3 mg of levonorgestrel, to a 200-mL volumetric flask. Dilute with *Mobile phase* to volume, sonicate to disintegrate the Tablets, then shake by mechanical means for 20 min. Centrifuge, and use the clear supernatant.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 215 nm

**Column:** 4.6-mm × 15-cm; 5- to 7-µm packing L7

**Flow rate:** 1 mL/min

**Injection size:** 50 µL

#### System suitability

**Sample:** *Standard solution*

[NOTE—The relative retention times for ethynodiol and levonorgestrel are about 0.7 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 2.5 between the two major peaks

**Relative standard deviation:** NMT 2.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of  $C_{21}H_{28}O_2$  and  $C_{20}H_{24}O_2$  in the portion of Tablets taken:

$$\text{Result} = \left( \frac{r_u}{r_s} \right) \times \left( \frac{C_s}{C_u} \right) \times 100$$

$r_u$  = peak response of the corresponding analyte from the *Sample solution*

$r_s$  = peak response of the corresponding analyte from the *Standard solution*

$C_s$  = concentration of the appropriate USP Reference Standard in the *Standard solution* ( $\mu\text{g/mL}$ )

$C_u$  = nominal concentration of the corresponding analyte in the *Sample solution* ( $\mu\text{g/mL}$ )

**Acceptance criteria:** 90.0%–110.0% of the labeled amount of  $\text{C}_{21}\text{H}_{28}\text{O}_2$ , 90.0%–110.0% of the labeled amount of  $\text{C}_{20}\text{H}_{24}\text{O}_2$

#### PERFORMANCE TESTS

- **Dissolution (711):** Determine the amount of  $\text{C}_{21}\text{H}_{28}\text{O}_2$  and  $\text{C}_{20}\text{H}_{24}\text{O}_2$  dissolved by employing the following method.

**Medium:** Polysorbate 80 (5  $\mu\text{g/g}$ ) in water; 500 mL

**Apparatus 2:** 75 rpm

**Time:** 60 min

**Mobile phase:** Acetonitrile and water (6:4)

**Standard solution:** Prepare a solution of [USP Levonorgestrel RS](#) and [USP Ethynodiol RS](#) in *Medium* having known concentrations corresponding approximately to the concentrations that would be obtained by dissolving 1 Tablet in 500 mL of *Medium*.

[**NOTE**—A volume of alcohol not exceeding 2% of the final total volume of solution may be used to aid in dissolving the Reference Standards.]

**Sample solution:** Withdraw 15-mL portions of liquid from each vessel, and pass through a polyvinylidene filter, discarding the first 10 mL of the filtrate.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 247 nm (for levonorgestrel analysis); a spectrofluorometric detector (for ethynodiol analysis), with an excitation wavelength of 285 nm, and an emission wavelength of 310 nm

**Column:** 4-mm  $\times$  15-cm; packing L7

**Flow rate:** 1 mL/min

**Injection size:** 100  $\mu\text{L}$

#### System suitability

**Sample:** *Standard solution*

[**NOTE**—The relative retention times for ethynodiol and levonorgestrel are about 0.7 and 1.0, respectively.]

#### Suitability requirements

**Relative standard deviation:** NMT 3.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of  $\text{C}_{21}\text{H}_{28}\text{O}_2$  and  $\text{C}_{20}\text{H}_{24}\text{O}_2$  dissolved:

$$\text{Result} = \left( \frac{r_u}{r_s} \right) \times \left( \frac{C_s}{C_u} \right) \times 100$$

$r_u$  = peak response of the corresponding analyte from the *Sample solution*

$r_s$  = peak response of the corresponding analyte from the *Standard solution*

$C_s$  = concentration of the appropriate USP Reference Standard in the *Standard solution* ( $\mu\text{g/mL}$ )

$C_u$  = nominal concentration of the corresponding analyte in the *Sample solution* ( $\mu\text{g/mL}$ )

#### Tolerances

**Uncoated Tablets:** NLT 80% (Q) of the labeled amount of  $\text{C}_{21}\text{H}_{28}\text{O}_2$ , and 75% (Q) of the labeled amount of  $\text{C}_{20}\text{H}_{24}\text{O}_2$  is dissolved.

**Coated Tablets:** NLT 60% (Q) of the labeled amount of  $\text{C}_{21}\text{H}_{28}\text{O}_2$  and  $\text{C}_{20}\text{H}_{24}\text{O}_2$  is dissolved.

- **Uniformity of Dosage Units (905):** Meet the requirements

**Sample solution:** Place 1 Tablet in a 40-mL centrifuge tube, add 10.0 mL of *Mobile phase*, and proceed as directed in the Assay.

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.

- [USP Reference Standards \(11\)](#).

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM52020 Small Molecules 5

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 36(1)

**Current DocID: GUID-6525900E-52A4-4ED1-8D89-574288EA4C21\_1\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M44830\\_01\\_01](https://doi.org/10.31003/USPNF_M44830_01_01)**

**DOI ref: [xd1wp](#)**

OFFICIAL